NCRI Lymphoma Trials Day

Friday 11ᵗʰ November 2022

Cavendish Conference Centre, 22 Duchess Mews, Marylebone, London

Current Chair: Andrew Pettitt
Incoming Chair: Andy Davies
Incoming Deputy Chair: Graham Collins

This important meeting for lymphoma trials will be held as face to face in 2022 and will be a welcome return to the event that was pre-covid held annually. There will be a full day of review of clinical trials by members of the NCRI Lymphoma Group. The format will be short presentations and discussion throughout the day.

The NCRI Lymphoma Group consists of an executive group, chaired by Professor Andrew Pettitt, which provides oversight of the research landscape and proactively identifies opportunities for the group. The NCRI Lymphoma Group also has several study groups that develop research in areas of strategic need.

08.45	*Registration*	
09.30	Welcome & overview of NCRI Lymphoma strategy	Andrew Pettitt
09.45	Low Grade Lymphoma NHL Study Group	Kim Linton
		Toby Eyre
	Discussion	
10.45	Hodgkin Lymphoma Study Group	Cathy Burton
	Discussion	
11.35	*Coffee*	
12.00	Health Data Research	Mark Bishton & David Cutter
12.20	**Mike Bennett Memorial Lecture**	
	Introduction	Andy Davies
	Guest International Speaker CART vs BITE, who goes first?	Gloria Iacoboni *Vall d'Hebron Hospital, Barcelona*
	Discussion	
13.15	*Lunch*	

14.10	Science Study Group	Daniel Hodson
14.30	High Grade NHL Study Group	Chris Fox

15.45   *Coffee*

16.00   Key ASH presentations (closed)

Michael Northend
Long Term Follow-up of International Randomised Phase 3 Study of Rituximab Versus a Watch and Wait Approach for Patients with Asymptomatic, Low Tumour Burden Follicular Lymphoma

William Townsend
8 year follow-up of the GALLIUM trial

Andy Davies
Five-Year Survival Results from the REMoDL-B Trial

Graham Collins
Final results from the RomiCar phase 1/2 study for relapsed/refractory PTCL

17.00   Close of meeting

Platinum Sponsors

Gold Sponsor

Exhibitors

The sponsors have supported the educational content of this event but had no influence over the content of the agenda or speaker selection.